Hospital
The Chambersburg Hospital
The Chambersburg Hospital was paid $10.29M by Medicaid between Jan 2018 and Dec 2024, across 129 billing codes. Its largest line is 99285, emergency room visit (most serious) — 38% of everything it billed.
33Billing provider infoTHE CHAMBERSBURG HOSPITAL
CHAMBERSBURG, PA 17201
CHAMBERSBURG, PA 17201
33aNPI1902804552assigned 07/08/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.29M
24GClaims249,695
24DCodes billed129
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#31 of 154
Median peer was paid$2.82M
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BUCZKOWSKI, LAURA controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 866 | $102K | |
| 2019 | 669 | $47K | |
| 2020 | 19,086 | $619K | |
| 2021 | 75,339 | $2.69M | |
| 2022 | 58,463 | $2.38M | |
| 2023 | 61,404 | $2.77M | |
| 2024incomplete | 33,868 | $1.67M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 38% | 21,461 | 20,011 | $3.90M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 18,564 | 17,855 | $2.17M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 13,563 | 12,663 | $1.94M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,058 | 1,994 | $350K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 8,665 | 8,300 | $221K |
| 80053 | Comprehensive metabolic panel | 2.0% | 24,026 | 23,089 | $210K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.2% | 683 | 677 | $128K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 26,968 | 25,783 | $125K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,400 | 1,342 | $89K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,816 | 6,498 | $88K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,092 | 3,873 | $72K |
| 84702 | <1% | 5,077 | 4,862 | $70K |
117 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,181 | $67K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,606 | $66K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 951 | $60K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 318 | $58K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,579 | $54K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,562 | $50K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 885 | $49K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 860 | $48K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,245 | $36K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 433 | $33K |
| 84484 | <1% | 3,864 | $32K | |
| 81001 | <1% | 13,439 | $32K | |
| 83690 | <1% | 7,116 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 272 | $22K |
| G0378 | Hospital observation service, per hour | <1% | 51 | $21K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 570 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 602 | $16K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 230 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 253 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,039 | $13K |
| 76830 | Ultrasound, transvaginal | <1% | 246 | $11K |
| 80050 | General health panel | <1% | 211 | $9K |
| 93971 | <1% | 161 | $9K | |
| 87040 | <1% | 437 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 594 | $7K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 212 | $7K |
| 76801 | <1% | 164 | $6K | |
| 85730 | <1% | 1,265 | $6K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 911 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 165 | $6K |
| 85379 | <1% | 604 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 409 | $5K |
| 85610 | <1% | 1,658 | $5K | |
| 83880 | <1% | 180 | $4K | |
| 83605 | <1% | 641 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 53 | $4K |
| 83735 | <1% | 843 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 612 | $4K |
| 73564 | <1% | 181 | $3K | |
| 73610 | <1% | 186 | $3K | |
| 90715 | <1% | 261 | $3K | |
| 82805 | <1% | 101 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 582 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 118 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,349 | $3K |
| 86850 | <1% | 365 | $3K | |
| 86901 | <1% | 581 | $3K | |
| 96376 | <1% | 170 | $3K | |
| 86900 | <1% | 581 | $3K | |
| 87077 | <1% | 379 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,963 | $2K |
| 87186 | <1% | 326 | $2K | |
| 82947 | <1% | 763 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 63 | $2K |
| 80076 | <1% | 297 | $2K | |
| 73030 | <1% | 146 | $2K | |
| 87631 | <1% | 13 | $2K | |
| 73130 | <1% | 168 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 95 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 94 | $2K |
| 73630 | <1% | 151 | $2K | |
| 70496 | <1% | 12 | $2K | |
| 80051 | <1% | 300 | $2K | |
| 82565 | <1% | 336 | $2K | |
| 93000 | <1% | 123 | $1K | |
| 84520 | <1% | 330 | $1K | |
| 73110 | <1% | 114 | $1K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 83 | $1K |
| 51701 | <1% | 57 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,858 | $1K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 141 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,673 | $1K |
| 82248 | <1% | 181 | $1K | |
| 70486 | <1% | 15 | $996.90 | |
| 86140 | <1% | 361 | $909.50 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 105 | $810.68 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,757 | $804.22 |
| 72131 | <1% | 14 | $770.90 | |
| 81025 | <1% | 217 | $695.77 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,364 | $681.53 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 69 | $649.31 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 109 | $539.94 |
| 82550 | <1% | 71 | $449.12 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,494 | $286.13 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,085 | $279.86 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 110 | $268.25 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 220 | $253.12 |
| 73590 | <1% | 16 | $231.86 | |
| 82010 | <1% | 60 | $229.25 | |
| 74018 | <1% | 16 | $205.91 | |
| 74022 | <1% | 12 | $201.98 | |
| A9270 | Non-covered item or service | <1% | 555 | $200.66 |
| 73502 | <1% | 12 | $187.81 | |
| 80061 | Lipid panel | <1% | 30 | $171.45 |
| 73090 | <1% | 13 | $163.36 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 724 | $133.84 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 56 | $133.01 |
| 93296 | <1% | 41 | $120.95 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 631 | $119.72 |
| 85027 | <1% | 41 | $109.47 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 44 | $106.48 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 33 | $56.51 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 133 | $51.86 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 110 | $49.19 |
| 81003 | <1% | 18 | $38.76 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 230 | $35.43 |
| J2704 | Injection, propofol, 10 mg | <1% | 173 | $28.10 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 212 | $15.07 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 33 | $14.65 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 47 | $0.00 |
| J3490 | Unclassified drugs | 0% | 232 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 34 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 133 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 25 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 62 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 29 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUCZKOWSKI, LAURA (SR VP AND CFO)
| Provider | Location | Paid |
|---|---|---|
| Our Lady of Bellefonte Hospital INC | Ashland, KY | $12.13M |
| Vna Home Health Services | York, PA | $3.99M |
| Waynesboro Hospital | Waynesboro, PA | $1.48M |
| Waynesboro Hospital | Fayetteville, PA | $831K |
| The Chambersburg Hospital | Chambersburg, PA | $801K |
| Wellspan Surgery and Rehabilitation Hospital | York, PA | $399K |
| Our Lady of Bellefonte Hospital INC | Ashland, KY | $200K |
| Waynesboro Hospital | Wayesboro, PA | $11K |
| The Chambersburg Hospital | Chambersburg, PA | $6K |
| The Chambersburg Hospital | Chambersburg, PA | $198.19 |
| Waynesboro Hospital | Waynesboro, PA | $6.58 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.